US · Healthcare · Medical Care Facilities
EPS came in at -0.36 against a street estimate of -0.46 — a beat of 21.7%.
Analysts rate Compass Pathways Plc a strong buy (11 buy, 0 hold, 0 sell out of 11) with an average price target of $23.75.
| Fund | Stake |
|---|---|
| Deep Track Capital, LP | 8.78% |
| RTW INVESTMENTS, LLC | 7.68% |
| Marshall Wace Asset Management Ltd | 2.92% |
| TANG CAPITAL MANAGEMENT LLC | 2.89% |
| ARK Investment Management LLC | 2.38% |
| GMT Capital Corp | 2.22% |
| Two Sigma Investments LLC | 1.87% |
| Dafna Capital Management LLC | 1.75% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 COMPASS PATHWAYS PLC — Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash position: $433.3 million as of June 30, 2026 (vs $149.6 million at December 31, | 2026-08-05 |
| Results announced · Q3 2026 COMPASS PATHWAYS PLC – Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Cash and cash equivalents: $433.3 million as of June 30, 2026 (vs. $149.6 millio | 2026-08-05 |
| Reg FD disclosure · Q3 2026 COMPASS PATHWAYS PLC – FORM 8-K SUMMARY HEADLINE NUMBERS • COMP006 Part B efficacy (26 weeks): 39% of participants in 25 mg arm achieved clinically | 2026-07-07 |
| Shareholder vote results · Q2 2026 COMPASS PATHWAYS PLC - FORM 8-K SUMMARY HEADLINE NUMBERS • Annual General Meeting (AGM) held May 27, 2026 with 58,880,058 ordinary shares represente | 2026-05-28 |
| Quarterly report · Q1 2026 COMPASS PATHWAYS PLC – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash position: $466.0 million as of March 31, 2026 (up from $149.6 million at Decembe | 2026-05-13 |
| Results announced · Q2 2026 COMPASS PATHWAYS PLC – Q1 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Net income $91.2 million for Q1 2026 vs. net loss of $17.9 million in Q1 | 2026-05-13 |
| Proxy statement · Q2 2026 COMPASS PATHWAYS PLC – 2026 AGM PROXY SUMMARY --- WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Re-elect Justin Gover as director (retiring by rota | 2026-04-15 |
| Annual report FY2025 COMPASS PATHWAYS PLC - 10-K SUMMARY HEADLINE NUMBERS • Company is a clinical-stage biotechnology firm focused on psilocybin-based mental health trea | 2026-03-24 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Compass Pathways Plc — free to start.
Google PlayApp StoreData updated 2026-09-18.